Treace Medical Concepts, Inc. (TMCI) stock
TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)
Close on Nov 17, 2026Market cap $288.75MP/E –Yield –
Treace Medical Concepts total assets
Total assets on the balance sheet at the end of each period.
Treace Medical Concepts's total assets was $181.06M at Jun 30, 2026. For fiscal 2025 it was $190.58M, down 12.2% from the year before. The highest annual figure on record is $251.91M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.58M | -12.2% |
| FY2024 | Dec 31, 2024 | $217.09M | -13.8% |
| FY2023 | Dec 31, 2023 | $251.91M | +58.4% |
| FY2022 | Dec 31, 2022 | $159.02M | +12.9% |
| FY2021 | Dec 31, 2021 | $140.82M | +236.8% |
| FY2020 | Dec 31, 2020 | $41.81M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $181.06M | -12.3% |
| Q1 FY2026 | Mar 31, 2026 | $184.10M | -10.6% |
| Q4 FY2025 | Dec 31, 2025 | $190.58M | -12.2% |
| Q3 FY2025 | Sep 30, 2025 | $196.59M | -7.7% |
| Q2 FY2025 | Jun 30, 2025 | $206.44M | -8.7% |
| Q1 FY2025 | Mar 31, 2025 | $205.85M | -15.2% |
| Q4 FY2024 | Dec 31, 2024 | $217.09M | -13.8% |
| Q3 FY2024 | Sep 30, 2024 | $212.92M | -11.4% |
| Q2 FY2024 | Jun 30, 2024 | $226.08M | -9.4% |
| Q1 FY2024 | Mar 31, 2024 | $242.73M | -2.6% |
| Q4 FY2023 | Dec 31, 2023 | $251.91M | +58.4% |
| Q3 FY2023 | Sep 30, 2023 | $240.36M | +53.6% |
| Q2 FY2023 | Jun 30, 2023 | $249.64M | +57.3% |
| Q1 FY2023 | Mar 31, 2023 | $249.17M | +70.1% |
| Q4 FY2022 | Dec 31, 2022 | $159.02M | +12.9% |
| Q3 FY2022 | Sep 30, 2022 | $156.44M | +13.7% |
| Q2 FY2022 | Jun 30, 2022 | $158.72M | +11.5% |
| Q1 FY2022 | Mar 31, 2022 | $146.51M | +291.9% |
| Q4 FY2021 | Dec 31, 2021 | $140.82M | +236.8% |
| Q3 FY2021 | Sep 30, 2021 | $137.59M | – |
| Q2 FY2021 | Jun 30, 2021 | $142.30M | – |
| Q1 FY2021 | Mar 31, 2021 | $37.38M | – |
| Q4 FY2020 | Dec 31, 2020 | $41.81M | – |
See a number that looks wrong?